ABSTRACT
Despite the successes of Viagra, the quest for new and better therapy for erectile dysfunction (ED) continues. In a recent survey of the first 220 patients placed on Viagra at our institution, 101 (46%) quit taking the drug: 76% of those who quit were not satisfied with the results. Patients clearly want an efficacious, safe, convenient medication with rapid onset. To meet these consumer demands, numerous new therapies are being developed. These include new oral medications, new intracavernosal pharmacotherapies, new delivery systems (such as novel intracorporal injectors and transdermal agents) and combination therapies. What is known about these new medications and delivery systems will be presented. Hopefully, from these innovations will come therapies that will improve the overall success and acceptance of treatment for ED. Since it is unlikely that any single agent will ever provide a solution for all men with ED, an expanded armamentarium of treatment options will greatly enhance the chances that any given man will be able to find a therapy that is both acceptable and appropriate to him. International Journal of Impotence Research (2000) 12, Suppl 4, S158-S162.
Subject(s)
Drug Delivery Systems , Erectile Dysfunction/drug therapy , Urology/methods , Urology/trends , Administration, Oral , Administration, Topical , Animals , Humans , Male , PenisSubject(s)
Appetite Depressants/adverse effects , Fenfluramine/adverse effects , Heart Valve Diseases/chemically induced , Phentermine/adverse effects , Serotonin/blood , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Drug Combinations , Female , Humans , Hydroxyindoleacetic Acid/urineABSTRACT
There has been a recent explosion of articles in the medical literature and newsbites on television and in the lay press regarding male menopause. Yet, many men are not familiar with the changes in sexuality that accompany aging. Primary care physicians therefore need to be well informed about the concept of male menopause and the dos, don'ts, and unknowns of treating it with testosterone.
Subject(s)
Aging , Middle Aged/physiology , Aged , Female , Humans , Male , Menopause , Reproduction , Sexuality , Testosterone/blood , Testosterone/therapeutic useSubject(s)
Antibodies, Monoclonal/immunology , Autoimmune Diseases/complications , Hypoglycemia/etiology , Insulin Antibodies/immunology , Multiple Myeloma/complications , Aged , Antibodies, Monoclonal/analysis , Autoimmune Diseases/immunology , Blood Glucose/metabolism , Eating , Humans , Insulin/blood , Insulin Antibodies/analysis , Male , Multiple Myeloma/immunologyABSTRACT
The medical records of 486 patients with pathologically proved squamous carcinoma of the skin of the external ear were analyzed. It is a disease of elderly white men, and the helix is the most common site of origin. Well-differentiated squamous carcinoma is the most frequent histologic variant. Ninety-five percent of our patients were treated surgically with above-clavical control in 87 percent and 28 percent survival. The low survival rate was related to the old age of the patients who frequently died of intercurrent disease and second cancers. A 12 percent incidence of nodal metastases is comparable with the incidence reported in other series. Aggressive surgical ablation and the selected use of adjunctive postoperative irradiation appear justified in those patients with locally invasive tumors, multiple nodal metastases, and extracapsular invasion.
